PCa Commentary | Volume 174 – February 2023
This Commentary discusses the importance of considering both PSA and PSA doubling time for determining biochemical recurrence.
Read MoreSelect Page
Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.
A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.
His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.
Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.
Posted by Edward Weber, MD | Feb 2023
This Commentary discusses the importance of considering both PSA and PSA doubling time for determining biochemical recurrence.
Read MorePosted by Edward Weber, MD | Jan 2023
This Commentary discusses Bipolar Androgen Therapy: an effective, but likely underused, option in the sequence of treatments for mCRPC.
Read MorePosted by Edward Weber, MD | Dec 2022
This Commentary discusses selecting men for MDT+ADT versus MDT alone in the oligometastatic prostate cancer space.
Read MorePosted by Edward Weber, MD | Nov 2022
This Commentary explores treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation for nmCRPC.
Read MorePosted by Edward Weber, MD | Sep 2022
This Commentary looks at ADT and radiotherapy, as well as evolution of cellular resistance to ADT therapy and potential treatment.
Read More